SanofiSNYNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank71
3Y CAGR-24.7%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-24.7%/yr
vs +16.5%/yr prior
Acceleration
-41.3pp
Decelerating
Percentile
P71
Within normal range
vs 3Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
20256.06%
202413.63%
20230.09%
202214.21%
20212.93%
2020-8.14%
20192.14%
20187.71%
20175.80%
20161.77%